SRJR Lifesciences LLP, the promoter of bafna pharmaceuticals , has confirmed that no encumbrance was created over the shares held by it in the company during the financial year ended March 31, 2026. This declaration, made directly or indirectly, ensures that the promoter's shareholding remains free from charges such as pledges or hypothecation for the specified period. The confirmation addresses potential concerns regarding the financial leveraging of promoter holdings, which is a key indicator of corporate governance for investors.

The disclosure was formally submitted to the stock exchanges, BSE Limited and National Stock Exchange of India Limited, on April 1, 2026. The communication was addressed to the General Managers of the Listing Departments at both exchanges and the Company Secretary of Bafna Pharmaceuticals Ltd. The filing was made in compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, which mandates promoters to disclose any encumbrance on their shareholdings annually.

Regulatory Filing Details

The letter, signed by Upendar Mekala Reddy, Designated Partner of SRJR Lifesciences LLP, provided specific identification details for the security. The confirmation covers the company's shares traded on the exchanges under the symbol BAFNAPH.

The promoter requested the exchanges to take the information on record and acknowledge receipt of the same. A copy of the disclosure was also marked to the Audit Committee of Bafna Pharmaceuticals Ltd.

bafna pharmaceuticals has scheduled a meeting of its Board of Directors for Friday, May 29, 2026. The primary agenda of the meeting is to consider and approve the audited financial results of the company for the quarter and year ended March 31, 2026. This intimation is made pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In accordance with the company’s Code of Conduct for Prevention of Insider Trading, the trading window for dealing in shares by designated persons and their immediate relatives has been closed. This closure is effective from April 01, 2026, and will remain in place until May 31, 2026, inclusive of both dates. The measure is intended to ensure compliance during the period leading up to the financial results announcement.

The company has requested the stock exchanges to take the above information on record. The intimation was signed by Mohanachandran A, Company Secretary & Compliance Officer, on May 21, 2026.

Key Details